Toxicity-guided dose modification for disseminated Nocardia farcinica brain abscess in a patient with pneumoconiosis: a brief research report
Frontiers in Pharmacology · 09.04.2026 · 17
DOI: 10.3389/fphar.2026.1805920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.04.2026. Verfasst von Hui Juan Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, 363 Hospital, Chengdu, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Optimal antimicrobial strategies for disseminated nocardiosis with central nervous system (CNS) involvement remain poorly defined, particularly regarding trimethoprim-sulfamethoxazole (TMP-SMX) dosing in immunocompromised patients with severe drug intolerance.
Methods
This observational case study analyzed the clinical course and pharmacological management of a 55-year-old male gold miner with pneumoconiosis and chronic corticosteroid use who developed Nocardia farcinica brain abscess. Diagnosis was established via metagenomic next-generation sequencing (mNGS) and phenotypic culture. An individualized antimicrobial regimen was designed based on toxicity monitoring.
Results
Diagnosis of N. farcinica was confirmed by mNGS within 48 h. The patient initially failed empirical meropenem but responded to combination therapy with imipenem, amikacin, and TMP-SMX. Due to grade III gastrointestinal toxicity (CTCAE v5.0), TMP-SMX was de-escalated from 15 mg·kg −1 ·d −1 –11.25 mg·kg −1 ·d −1 , with maintenance at 7.5 mg·kg −1 ·d −1 . Clinical improvement was observed at Day 120, though durable cure remains unconfirmed.
Conclusion
In extreme circumstances of severe dose-limiting toxicity, temporary TMP-SMX dose reduction with intensive monitoring may be feasible as a bridge to complete guideline-concordant therapy, though this approach falls below current recommendations and requires robust therapeutic drug monitoring. Species-directed antimicrobial selection and early molecular diagnosis facilitated initial clinical resolution in this high-risk immunocompromised host.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, 363 Hospital, Chengdu, China.
- Department of Neurosurgery, 363 Hospital, Chengdu, China.
- Department of Clinical Laboratory, 363 Hospital, Chengdu, China.
Zitieren
APA
Liu, H. J., Wang, L. F., Li, X. Y., & Li, L. (2026). Toxicity-guided dose modification for disseminated Nocardia farcinica brain abscess in a patient with pneumoconiosis: a brief research report. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1805920
Vancouver
Liu HJ, Wang LF, Li XY, Li L. Toxicity-guided dose modification for disseminated Nocardia farcinica brain abscess in a patient with pneumoconiosis: a brief research report. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1805920
BibTeX
@article{Liu2026,
author = {Liu, Hui Juan and Wang, Liang Fen and Li, Xiao Yue and Li, Ling},
title = {Toxicity-guided dose modification for disseminated Nocardia farcinica brain abscess in a patient with pneumoconiosis: a brief research report},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1805920}
}
EUVIMED